

### Results in Brief

	Six Months Ended 30 Sep 21 NZ\$M (except as otherwise stated)	Six Months Ended 30 Sep 22 NZ\$M (except as otherwise stated)	% Change (Reported)	% Change (Constant Currency <sup>1</sup> )
<b>FINANCIAL PERFORMANCE</b>				
<b>Total operating revenue</b>	<b>900.0</b>	<b>690.6</b>	-23%	<b>-27%</b>
Cost of sales	(332.3)	(277.4)	-17%	-16%
Gross profit	567.7	413.2	-27%	-33%
Gross margin	63.1%	59.8%	-325bps	-533bps
Selling, general and administrative expenses	(189.6)	(202.3)	+7%	-%
Research and development expenses	(75.7)	(84.2)	+11%	+11%
R&D percentage of operating revenue	8.4%	12.2%	+378bps	+445bps
<b>Total operating expenses</b>	<b>(265.3)</b>	<b>(286.5)</b>	+8%	<b>+3%</b>
Operating profit before financing costs	302.4	126.7	-58%	-67%
Operating margin	33.6%	18.3%	-1526bps	-1770bps
Net financing income (expense)	(1.3)	(12.4)	+854%	-125%
Profit before tax	301.1	114.3	-62%	-67%
Tax expense	(79.3)	(18.4)	-77%	-74%
<b>Profit after tax</b>	<b>221.8</b>	<b>95.9</b>	-57%	<b>-65%</b>
Effective tax rate	<b>26.3%</b>	<b>16.1%</b>		
Effective tax rate excluding R&D tax credit	<b>28.8%</b>	<b>22.7%</b>		
<b>Revenue by Region:</b>				
North America	329.8	289.5	-12%	
Europe	232.0	188.0	-19%	
Asia Pacific	267.2	174.2	-35%	
Other	71.0	38.9	-45%	
<b>Total</b>	<b>900.0</b>	<b>690.6</b>	-23%	
<b>Revenue by Product Group:</b>				
Hospital	670.2	438.7	-35%	
Homecare	226.9	249.9	+10%	
Core products sub-total	897.1	688.6	-23%	
Distributed and other	2.9	2.0	-32%	
<b>Total</b>	<b>900.0</b>	<b>690.6</b>	-23%	
<b>FINANCIAL POSITION</b>				
	As at 31 Mar 22 NZ\$M (except as otherwise stated)	As at 30 Sep 22 NZ\$M (except as otherwise stated)		
Tangible assets	1,936.6	1,837.8	-5%	
Intangible assets <sup>2</sup>	170.4	256.7	+51%	
Total assets	2,107.0	2,094.5	-1%	
Total liabilities	(427.3)	(616.1)	+44%	
<b>Shareholders' equity</b>	<b>1,679.7</b>	<b>1,478.4</b>	-12%	
Gearing	-16.3%	2.7%	+19%	
Net tangible asset backing (cents per share)	261	211	-19%	

<sup>1</sup> Constant currency (CC) removes the impact of exchange rate movements. This approach is used to assess the Group's underlying comparative financial performance without any impact from changes in foreign exchange rates. The company's constant currency framework can be found on the company's website at [www.fphcare.com/ccf](http://www.fphcare.com/ccf). The reconciliation to reported results is included within the Financial Commentary section of the Interim Report.

<sup>2</sup> Includes Intangible and deferred tax assets.

## Results in Brief (continued)

	Six Months Ended 30 Sep 21 NZ\$M (except as otherwise stated)	Six Months Ended 30 Sep 22 NZ\$M (except as otherwise stated)	% Change
<b>CASH FLOWS</b>			
Net cash flow from operating activities	127.5	1.9	-99%
Net cash flow (used in) investing activities	13.8	75.2	+445%
Net cash flow (used in) financing activities	(131.9)	(107.5)	-19%
<b>SHARES OUTSTANDING</b>			
Weighted average basic shares outstanding	576,615,929	577,490,656	
Weighted average diluted shares outstanding	579,772,363	580,504,570	
Basic shares outstanding at period end	577,131,310	577,663,664	
<b>DIVIDENDS AND EARNINGS PER SHARE</b>			
Dividends per share (cents) – declared	17.0	17.5	+3%
Basic earnings per share (cents)	38.5	16.6	-57%